Experts from the FDA and CDC continue their discussion on tecovirimat, or TPOXX, for the treatment of monkeypox in infected individuals. In part two of this mini-series, experts answer physicians' questions about treatment for monkeypox. Guests include Adam Sherwat, MD, Deputy Director, Office of Infectious Disease at FDA’s Center for Drug Evaluation and Research; Brett W. Petersen, MD, MPH, Deputy Chief, Poxvirus and Rabies Branch, CDC’s Division of High-Consequence Pathogens and Pathology; and Timothy Wilkin, MD, MPH, Professor of Medicine and Assistant Dean for Clinical Research Compliance for Human Research Protections at Weill Cornell Medicine and TPOXX clinical trial lead.? Follow the AMA on YouTube: @americanmedicalassociation

 ? Watch #AMAUpdate for the latest in health care news for physicians:
https://bit.ly/AMA_Update

? Subscribe to AMA Morning Rounds newsletter, with the news you need
every morning delivered to your inbox: https://bit.ly/AMA-MorningRounds 

? Listen to our latest podcast episodes now:
https://bit.ly/AMA_Podcasts 

? Download AMA Connect for news, podcasts, video updates and learning in
one place: https://apple.co/3URzNES